Biogen Inc
NASDAQ: BIIB
$199.36
-$2.08 (-1.0%)
Closing Price on September 20, 2024
BIIB Articles
Biogen reported better-than-expected third-quarter financial results before the markets opened on Wednesday,
Published:
Last Updated:
The October 14 short interest data have been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
Last Updated:
Earnings season is now in full swing, and we have put together a preview of Bristol-Myers, AbbVie and some of the other top players in the health care sector.
Published:
Last Updated:
These top biotech companies have been absolutely hammered and now trade at a valuation much lower than large cap pharmaceuticals.
Published:
Last Updated:
If a single failed clinical trial can mean disaster for a biotech stock, then short sellers can argue for a stock implosion down the road.
Published:
Last Updated:
Over the past week, a few biotech companies made absolutely massive runs. The companies 24/7 Wall St. has picked stood out from the rest with at least 25% gains.
Published:
Last Updated:
Shares of Anavex Life Sciences soared on Wednesday following a material transfer agreement with Biogen.
Published:
Last Updated:
The September 15 short interest data have been compared with the previous report, and short interest moves were upward across most of these selected biotech stocks.
Published:
Last Updated:
The August 31 short interest data have been compared with the previous report, and short interest decreased for most of these selected biotech stocks.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Biogen, Broadcom, Devon Energy, Gilead Sciences, Mondelez and Urban Outfitters.
Published:
Last Updated:
The August 15 short interest data have been compared with the previous report, and short interest moves were mixed across these selected biotech stocks.
Published:
Last Updated:
Investors are now focusing on fundamentals and near-term catalysts that could provide a tailwind for some of the biotech leaders.
Published:
Last Updated:
The short interest data are out for the July 29 settlement date and short interest decreased across these selected biotech stocks.
Published:
Last Updated:
Though these four large cap biotech stocks are cheap relative to the S&P 500, history says they won’t stay that way.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include Biogen, Discovery Communications, Mosaic, Plains All American, Phillips 66 and Rubicon Project.
Published:
Last Updated: